France‑based Ocean Diagnostics reported a pilot clinical evaluation showing its rapid sepsis identification test matched conventional blood cultures at 100% concordance and correlated strongly with mass spectrometry. The platform combines high‑volume sample prep, pan‑bacterial PCR, nanopore sequencing and a pathogen database to analyze viable bacterial cells from up to 10 mL whole blood, delivering results in about five hours with a roadmap to 3.5 hours. The company plans clinical trials next year for CE marking and later seeks FDA clearance. Investigators highlighted the test’s ability to detect culture‑negative pathogens and samples taken during antibiotic treatment, a key limitation of standard blood culture workflows.